Literature DB >> 8064663

Treatment of tumor-bearing dogs with actinomycin D.

A S Hammer1, C G Couto, R D Ayl, K A Shank.   

Abstract

Fifty dogs with advanced malignancies were treated with actinomycin D at doses ranging from 0.5 to 1.1 mg/m2 every 3 weeks. The greatest number of responses was noted in dogs with lymphoma, including dogs that had received prior chemotherapy. Other responding tumor types included anal sac adenocarcinoma, perianal adenocarcinoma, squamous cell carcinoma, thyroid carcinoma, and transitional cell carcinoma. The median time to maximum response for dogs with lymphoma was 7 days, with a median duration of 42 days. Gastrointestinal toxicity was the most frequently observed side effect. A dose of 0.6 to 0.7 mg/m2 appears to be appropriate for treating various malignancies in dogs.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8064663     DOI: 10.1111/j.1939-1676.1994.tb03224.x

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  7 in total

Review 1.  External beam radiation therapy for thyroid cancer in the dog.

Authors:  Monique N Mayer; Valerie S MacDonald
Journal:  Can Vet J       Date:  2007-07       Impact factor: 1.008

2.  The efficacy and adverse event profile of dexamethasone, melphalan, actinomycin D, and cytosine arabinoside (DMAC) chemotherapy in relapsed canine lymphoma.

Authors:  Melissa Parsons-Doherty; Valerie J Poirier; Gabrielle Monteith
Journal:  Can Vet J       Date:  2014-02       Impact factor: 1.008

3.  Evaluation of an actinomycin-D-containing combination chemotherapy protocol with extended maintenance therapy for canine lymphoma.

Authors:  Cecile T Siedlecki; Philip H Kass; Martin J Jakubiak; Gillian Dank; Jarred Lyons; Michael S Kent
Journal:  Can Vet J       Date:  2006-01       Impact factor: 1.008

4.  Evaluation of adjuvant carboplatin chemotherapy in the management of surgically excised anal sac apocrine gland adenocarcinoma in dogs.

Authors:  R M Wouda; J Borrego; N S Keuler; T Stein
Journal:  Vet Comp Oncol       Date:  2013-10-24       Impact factor: 2.613

5.  Anti-tumor effects of nitrosylcobalamin against spontaneous tumors in dogs.

Authors:  Joseph A Bauer; Gerald Frye; Anne Bahr; Jennifer Gieg; Peter Brofman
Journal:  Invest New Drugs       Date:  2009-06-27       Impact factor: 3.850

6.  Early tumor response to intraarterial or intravenous administration of carboplatin to treat naturally occurring lower urinary tract carcinoma in dogs.

Authors:  W T N Culp; C Weisse; A C Berent; J A Reetz; E L Krick; D E Jackson; P H Kass; C A Clifford; K U Sorenmo
Journal:  J Vet Intern Med       Date:  2015-04-21       Impact factor: 3.333

7.  Evaluation of toceranib for treatment of apocrine gland anal sac adenocarcinoma in dogs.

Authors:  Caitlin M Heaton; Arthur F A Fernandes; Paulo C Jark; Xuan Pan
Journal:  J Vet Intern Med       Date:  2020-01-24       Impact factor: 3.333

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.